Dose-equivalence by class

ARB dose calculator: % of maximum

ARB (sartan) comparison

Selected ARB

— in the «Доступні ліки» state reimbursement register

No validated method available

There is no validated mg-for-mg conversion between ARBs (sartans). Compare ARBs at the same percentage of each drug's own licensed maximum dose instead. We will not invent a conversion ratio.

Suggested alternative: Compare ARBs at the same percentage of each drug's licensed maximum dose, and titrate against measured blood pressure.

Modeled position on the dose range

Losartan
50%

Evidence: 3 of 5 stars: Reasonable method with moderate or indirect supporting evidence.

25%
50%
50%
10 mg · start100 mg · licensed max
Losartan on its own licensed dose range (Makani 2014)

At about 50% of max, the pooled 24-hour ambulatory drop was 11.7/7.6 mmHg (systolic/diastolic).

Potency rankingLower SUCRA rank (Zhang 2024). This is an ordinal ranking only: never a dose ratio.
Why this estimate & cautions
Shallow dose-responseThe ARB dose-response curve is shallow: doubling the dose adds under 2 mmHg systolic or diastolic. Compare ARBs at the same % of licensed maximum, not mg-for-mg.
Equal %-of-max ≠ equal BP drop
Source
  • Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH (2014) (opens in a new tab) Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J. Identifier: PMID 23966312; PMCID PMC5994844
    Verbatim from the source:
    the dose–response curve with ARBs was shallow with decrease of 10.3/6.7 (systolic/diastolic), 11.7/7.6, and 13.0/8.3 mmHg with 25% max dose, 50% max dose, and with the max dose of ARBs, respectively. … doubling the dose merely increased the antihypertensive efficacy by <2 mmHg systolic or diastolic.
  • Zhang Z, Yang H, Guo H (2024) (opens in a new tab) Comparative efficacy and safety of six angiotensin receptor blockers in hypertensive patients: a network meta-analysis. Int J Clin Pharm. Identifier: PMID 38861046
    Verbatim from the source:
    Olmesartan had the highest surface under the cumulative ranking in reducing office systolic (91.4%) and diastolic blood pressure (87.2%). … Valsartan and losartan were less effective in lowering blood pressure than other drugs.
The maximum achievable blood-pressure reduction differs between ARBs (olmesartan reaches a higher ceiling than losartan or valsartan), so the same fraction of each drug's own maximum does not guarantee the same mmHg (Makani 2014; Zannad 2007; Kassler-Taub 1998).
Losartan is a class outlier
Source
  • Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH (2014) (opens in a new tab) Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J. Identifier: PMID 23966312; PMCID PMC5994844
    Verbatim from the source:
    Losartan in the dose of 50 mg lowered ABP less well than other ARBs at 50% max dose by 2.5 mmHg systolic (P < 0.0001) and 1.8 mmHg diastolic (P = 0.0003). … Blood pressure reduction with losartan at starting dose and at max dose was consistently inferior to the other ARBs.
Losartan is weaker per dose and gives poorer 24-hour once-daily coverage than the other ARBs. Its blood-pressure reduction was consistently inferior at both starting and maximum dose (Makani 2014).
Single-ingredient comparison onlyThis compares single-ingredient ARB tablets. Fixed-dose combinations (for example telmisartan + amlodipine + hydrochlorothiazide, such as Telmista Trio) are out of scope. Their components cannot be compared on this axis, and combination tablets must not be split or crushed to separate them.

Licensed maximum dose chart, by drug

No validated milligram-for-milligram conversion exists between ARBs; this table shows each drug's maximum licensed dose, the basis for comparing them at the same % of maximum. Losartan is the class outlier — weaker per dose with poorer 24-hour once-daily coverage — so an equal % of maximum does not make it equivalent to the others. Educational only, not a prescription.

DrugLicensed maximum
Losartan100 mg
Valsartan320 mg
Telmisartan80 mg
Olmesartan40 mg
Candesartan32 mg
Irbesartan300 mg

There is no validated milligram-for-milligram conversion between ARBs such as losartan and valsartan; the evidence compares them at the same percentage of each drug's maximum licensed dose, so this page refuses a fixed ratio and shows the %-of-max basis — educational only, not a prescription.

Evidence

References2

Original

Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH (2014) (opens in a new tab) Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. Eur Heart J.

Supporting

Zhang Z, Yang H, Guo H (2024) (opens in a new tab) Comparative efficacy and safety of six angiotensin receptor blockers in hypertensive patients: a network meta-analysis. Int J Clin Pharm.

Method review — pending

Data current as of July 2026.

Educational PK model: not clinical guidance. Confirm any dose change with a prescriber or pharmacist.